RMTG's Cellgenic Division Introduces MUSE Cell Product Line Across Four International Regions

Nvidia CEO Jensen Huang announced a plan to accelerate AI data center construction, introducing the DSX POD design for rapid deployment. Nvidia claims these centers can be operational in 14 days, significantly reducing setup time. The company reported strong Q2 revenue growth, driven by data center sales. Huang emphasized the financial impact of delays, stating a $50 billion data center could generate $40 billion annually in revenue.

Moderna and Merck reported that their mRNA cancer vaccine, intismeran, reduced death or recurrence risk by 42% in a late-stage melanoma trial. The vaccine, combined with Merck's Keytruda, showed improved recurrence-free and metastasis-free survival rates compared to Keytruda alone. The companies plan to seek regulatory approval and presented the data at a medical conference.

AbbVie (NYSE:ABBV) shares have risen 26% this year due to strong financial performance. The company's growth is driven by Skyrizi and Rinvoq, with Skyrizi generating $10B in H1 sales. AbbVie is developing ABBV-466, a potential successor to Skyrizi, and acquired Apogee Therapeutics for $10.9B to bolster its immunology portfolio. The company also has a strong pipeline and a 2.5% dividend yield.

Albany International Corp. (AIN) expanded its AEC unit's hypersonic, solid rocket motor, and space manufacturing capabilities via AEC-AP after a $36M investment and a $21.2M, 30-month IBAS contract. The facility in Rochester, NH will support carbon-carbon TPS and related hardware, aligning with defense composites demand.

RBC Capital reiterated a Sector Perform rating and $145 price target for Merck (MRK) after melanoma trial data showed a recurrence-free survival hazard ratio of 0.58. The stock is near its 52-week high, up 76% year-to-date. Analysts expect regulatory filings in the U.S. and Europe, with FDA approval anticipated in 2027. Merck is set to announce earnings on October 29, with mixed analyst expectations.

JPMorgan Chase (JPM) blocked outside AI agents from moving customer deposits and expanded its JPM Coin to Ethereum for institutional clients. The bank's 2027 interest income outlook relies heavily on deposit and card-loan growth. Shares closed at $335.19, up 4.0% in 2026. Q3 earnings missed estimates, with adjusted EPS of $5.75 vs. $5.94 expected. Analysts' target price is ~$373, with a potential total return of ~31%.